Verona COPD drug beats Boehringer blockbuster in phase 2 by Nick Paul Taylor Thursday, September 7, 2017 Data from the phase 2a trial suggest Verona’s PDE3/PDE4 inhibitor may complement long-acting muscarinic antagonist bronchodilators such as Spiriva.
